Semaglutide doubles risk for nonarteritic anterior ischemic optic neuropathy

Use of once-weekly semaglutide more than doubles the risk for nonarteritic anterior ischemic optic neuropathy (NAION) in individuals with type 2 diabetes, according to a study published online Dec. 18 in the International Journal of Retina and Vitreous.

Leave A Comment

Your email address will not be published. Required fields are marked *